Build Your Comparison

Side-by-side financial analysis
KLTO logo
KLTO
ACIU logo
ACIU
KO logo
KO
Try popular comparisons:

Stock Comparison

KLTO vs ACIU vs KO

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
KLTO
Klotho Neurosciences, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$7M
5Y Perf.-59.1%
ACIU
AC Immune S.A.

Biotechnology

HealthcareNASDAQ • CH
Market Cap$235M
5Y Perf.-9.3%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$355.61B
5Y Perf.+12.5%

KLTO vs ACIU vs KO — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
KLTO logoKLTO
ACIU logoACIU
KO logoKO
IndustryBiotechnologyBiotechnologyBeverages - Non-Alcoholic
Market Cap$7M$235M$355.61B
Revenue (TTM)$0.00$4M$49.28B
Net Income (TTM)$-11M$-70M$13.70B
Gross Margin100.0%61.7%
Operating Margin-19.3%29.3%
Forward P/E25.3x
Total Debt$272K$5M$45.49B
Cash & Equiv.$64K$27M$10.27B

KLTO vs ACIU vs KOLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

KLTO
ACIU
KO
StockAug 24Mar 26Return
Klotho Neuroscience… (KLTO)10040.9-59.1%
AC Immune S.A. (ACIU)10090.7-9.3%
The Coca-Cola Compa… (KO)100112.5+12.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: KLTO vs ACIU vs KO

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: KO leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. AC Immune S.A. is the stronger pick specifically for capital preservation and lower volatility. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇KO emerged as the overall leader. Track its performance:
KLTO
Klotho Neurosciences, Inc.
The Secondary Option

KLTO plays a supporting role in this comparison — it may shine differently against other peers.

Best for: healthcare exposure
ACIU
AC Immune S.A.
The Income Pick

ACIU is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • beta 1.69
  • Lower volatility, beta 1.69, Low D/E 10.1%, current ratio 1.02x
  • Beta 1.69, current ratio 1.02x
Best for: income & stability and sleep-well-at-night
KO
The Coca-Cola Company
The Growth Play

KO carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 1.9%, EPS growth 23.6%, 3Y rev CAGR 3.7%
  • 121.1% 10Y total return vs KLTO's -63.0%
  • 1.9% revenue growth vs KLTO's -49.0%
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthKO logoKO1.9% revenue growth vs KLTO's -49.0%
Quality / MarginsKO logoKO27.8% margin vs ACIU's -19.7%
Stability / SafetyACIU logoACIUBeta 1.69 vs KLTO's 1.91, lower leverage
DividendsKO logoKO2.5% yield; 56-year raise streak; the other 2 pay no meaningful dividend
Momentum (1Y)KO logoKO+17.2% vs KLTO's -81.0%
Efficiency (ROA)KO logoKO13.1% ROA vs KLTO's -112.1%, ROIC 15.8% vs -242.3%

KLTO vs ACIU vs KO — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

KLTOKlotho Neurosciences, Inc.

Segment breakdown not available.

ACIUAC Immune S.A.

Segment breakdown not available.

KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B

KLTO vs ACIU vs KO — Financial Metrics

Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLKOLAGGINGKLTO

Income & Cash Flow (Last 12 Months)

KO leads this category, winning 4 of 6 comparable metrics.

KO and KLTO operate at a comparable scale, with $49.3B and $0 in trailing revenue. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to ACIU's -19.7%. On growth, KO holds the edge at +12.1% YoY revenue growth, suggesting stronger near-term business momentum.

MetricKLTO logoKLTOKlotho Neuroscien…ACIU logoACIUAC Immune S.A.KO logoKOThe Coca-Cola Com…
RevenueTrailing 12 months$0$4M$49.3B
EBITDAEarnings before interest/tax-$8M-$67M$15.5B
Net IncomeAfter-tax profit-$11M-$70M$13.7B
Free Cash FlowCash after capex-$6M-$70M$12.6B
Gross MarginGross profit ÷ Revenue+100.0%+61.7%
Operating MarginEBIT ÷ Revenue-19.3%+29.3%
Net MarginNet income ÷ Revenue-19.7%+27.8%
FCF MarginFCF ÷ Revenue-19.6%+25.5%
Rev. Growth (YoY)Latest quarter vs prior year-70.3%+12.1%
EPS Growth (YoY)Latest quarter vs prior year+72.9%+6.7%+18.2%
KO leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

ACIU leads this category, winning 2 of 3 comparable metrics.
MetricKLTO logoKLTOKlotho Neuroscien…ACIU logoACIUAC Immune S.A.KO logoKOThe Coca-Cola Com…
Market CapShares × price$7M$235M$355.6B
Enterprise ValueMkt cap + debt − cash$8M$207M$390.8B
Trailing P/EPrice ÷ TTM EPS-1.19x-2.63x27.18x
Forward P/EPrice ÷ next-FY EPS est.25.27x
PEG RatioP/E ÷ EPS growth rate2.43x
EV / EBITDAEnterprise value multiple26.39x
Price / SalesMarket cap ÷ Revenue52.43x7.42x
Price / BookPrice ÷ Book value/share6.19x4.13x10.40x
Price / FCFMarket cap ÷ FCF67.15x
ACIU leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

KO leads this category, winning 6 of 9 comparable metrics.

KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-114 for KLTO. ACIU carries lower financial leverage with a 0.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to KO's 1.33x. On the Piotroski fundamental quality scale (0–9), KO scores 7/9 vs ACIU's 2/9, reflecting strong financial health.

MetricKLTO logoKLTOKlotho Neuroscien…ACIU logoACIUAC Immune S.A.KO logoKOThe Coca-Cola Com…
ROE (TTM)Return on equity-113.7%-101.6%+41.1%
ROA (TTM)Return on assets-112.1%-38.7%+13.1%
ROICReturn on invested capital-2.4%-99.2%+15.8%
ROCEReturn on capital employed-6.2%-72.6%+17.3%
Piotroski ScoreFundamental quality 0–9427
Debt / EquityFinancial leverage0.23x0.10x1.33x
Net DebtTotal debt minus cash$208,012-$22M$35.2B
Cash & Equiv.Liquid assets$63,741$27M$10.3B
Total DebtShort + long-term debt$271,753$5M$45.5B
Interest CoverageEBIT ÷ Interest expense-1.98x-482.85x10.70x
KO leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

KO leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in KO five years ago would be worth $16,560 today (with dividends reinvested), compared to $3,117 for ACIU. Over the past 12 months, KO leads with a +17.2% total return vs KLTO's -81.0%. The 3-year compound annual growth rate (CAGR) favors KO at 13.7% vs KLTO's -28.2% — a key indicator of consistent wealth creation.

MetricKLTO logoKLTOKlotho Neuroscien…ACIU logoACIUAC Immune S.A.KO logoKOThe Coca-Cola Com…
YTD ReturnYear-to-date+19.1%-31.3%+20.3%
1-Year ReturnPast 12 months-81.0%+11.6%+17.2%
3-Year ReturnCumulative with dividends-63.0%+8.5%+47.0%
5-Year ReturnCumulative with dividends-63.0%-68.8%+65.6%
10-Year ReturnCumulative with dividends-63.0%-85.2%+121.1%
CAGR (3Y)Annualised 3-year return-28.2%+2.7%+13.7%
KO leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

KO leads this category, winning 2 of 2 comparable metrics.

KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than KLTO's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.3% from its 52-week high vs KLTO's 15.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricKLTO logoKLTOKlotho Neuroscien…ACIU logoACIUAC Immune S.A.KO logoKOThe Coca-Cola Com…
Beta (5Y)Sensitivity to S&P 5001.91x1.69x-0.20x
52-Week HighHighest price in past year$2.45$4.00$84.04
52-Week LowLowest price in past year$0.21$1.65$65.35
% of 52W HighCurrent price vs 52-week peak+15.6%+57.8%+98.3%
RSI (14)Momentum oscillator 0–10061.934.760.6
Avg Volume (50D)Average daily shares traded95K294K12.7M
KO leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: ACIU as "Buy", KO as "Buy". Consensus price targets imply 203.0% upside for ACIU (target: $7) vs 4.2% for KO (target: $86). KO is the only dividend payer here at 2.46% yield — a key consideration for income-focused portfolios.

MetricKLTO logoKLTOKlotho Neuroscien…ACIU logoACIUAC Immune S.A.KO logoKOThe Coca-Cola Com…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$7.00$86.13
# AnalystsCovering analysts948
Dividend YieldAnnual dividend ÷ price+2.5%
Dividend StreakConsecutive years of raises56
Dividend / ShareAnnual DPS$2.04
Buyback YieldShare repurchases ÷ mkt cap+1.6%0.0%+0.2%
Insufficient data to determine a leader in this category.
Key Takeaway

KO leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ACIU leads in 1 (Valuation Metrics).

Best OverallThe Coca-Cola Company (KO)Leads 4 of 6 categories
Loading custom metrics...

KLTO vs ACIU vs KO: Key Questions Answered

9 questions · data-driven answers · updated daily

01

Is KLTO or ACIU or KO a better buy right now?

For growth investors, The Coca-Cola Company (KO) is the stronger pick with 1.

9% revenue growth year-over-year, versus -86. 9% for AC Immune S. A. (ACIU). The Coca-Cola Company (KO) offers the better valuation at 27. 2x trailing P/E (25. 3x forward), making it the more compelling value choice. Analysts rate AC Immune S. A. (ACIU) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — KLTO or ACIU or KO?

Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.

6%, compared to -68. 8% for AC Immune S. A. (ACIU). Over 10 years, the gap is even starker: KO returned +121. 1% versus ACIU's -85. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — KLTO or ACIU or KO?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Klotho Neurosciences, Inc. 's 1. 91β — meaning KLTO is approximately -1055% more volatile than KO relative to the S&P 500. On balance sheet safety, AC Immune S. A. (ACIU) carries a lower debt/equity ratio of 10% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.

04

Which is growing faster — KLTO or ACIU or KO?

By revenue growth (latest reported year), The Coca-Cola Company (KO) is pulling ahead at 1.

9% versus -86. 9% for AC Immune S. A. (ACIU). On earnings-per-share growth, the picture is similar: The Coca-Cola Company grew EPS 23. 6% year-over-year, compared to -37. 3% for AC Immune S. A.. Over a 3-year CAGR, KO leads at 3. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — KLTO or ACIU or KO?

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -1971. 6% for AC Immune S. A. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -1927. 3% for ACIU. At the gross margin level — before operating expenses — ACIU leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is KLTO or ACIU or KO more undervalued right now?

Analyst consensus price targets imply the most upside for ACIU: 203.

0% to $7. 00.

07

Which pays a better dividend — KLTO or ACIU or KO?

In this comparison, KO (2.

5% yield) pays a dividend. KLTO, ACIU do not pay a meaningful dividend and should not be held primarily for income.

08

Is KLTO or ACIU or KO better for a retirement portfolio?

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Klotho Neurosciences, Inc. (KLTO) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, KLTO: -63. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between KLTO and ACIU and KO?

These companies operate in different sectors (KLTO (Healthcare) and ACIU (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

KO pays a dividend while KLTO, ACIU do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.